2022-12-30
China Medical System (867.HK) won the Awards of “Listed Biopharma with the Most Growing Value” and “Overseas Listed Company with the Most Growing Value”.
On December 28, the rank of “the 12th China’s Top Listed Companies by popularity 2022” was grandly released. China Medical System Holdings Limited (“CMS” or the “Group”) won both the awards of “Listed Biopharma with the Most Growing Value” and “Overseas Listed Company with the Most Growing Value”. The rank of Top Listed Companies by popularity was held by The National Business Daily, aiming to build reputation and create value for the capital market. This year the selection went through four stages, these are public nomination, big data screening, model screening, and institution + public voting. After more than 3 months of selection, nearly 3,000 listed companies were nominated, and 15 major awards were finally released. Winning both awards reflects the comprehensive strength of CMS in the bio-pharmaceutical industry and demonstrates high affirmation from capital market on its quality development. In recent years, CMS has driven its development through innovation, continuously strengthened the open platform, and joined hands with global biotechnology innovation companies to develop differentiated innovative products to meet […]
Learn More